Which countries run stem-cell trials for Liver Cirrhosis?
19 countries host at least one registered site; China alone accounts for around 54% of mentions in this snapshot (2026-08-29).
Country distribution
| Country | Studies with a site there |
|---|---|
| China | 38 |
| Iran | 6 |
| Vietnam | 4 |
| South Korea | 4 |
| Turkey (Türkiye) | 4 |
| Japan | 3 |
| Indonesia | 3 |
| Singapore | 3 |
| India | 3 |
| Italy | 2 |
A study with sites in several countries is counted once per country, taken from the location block of each registry record.
What the map means for Liver Cirrhosis
Registered work clusters where hepatology and transplant services coexist, particularly in Asia and parts of Europe. Because transplant is the established option, the honest question for any overseas offer is how it affects transplant candidacy and follow-up at home.
Where recruitment is actually open
| Country | Open studies with a site there |
|---|---|
| China | 3 |
| South Korea | 1 |
| Turkey (Türkiye) | 1 |
| France | 1 |
What travelling for a trial actually involves
Cross-border participation fails on logistics more often than on eligibility: follow-up schedules, local insurance, visa duration and who pays for complications. A site that cannot answer those in writing is not going to enrol you.
Multi-country studies, named
Registered studies with sites in more than one country — the clearest evidence of collaboration rather than a single-centre series.
- NCT06823713 — RTX001 Autologous Engineered Macrophages for Liver Cirrhosis (Spain, United Kingdom)
Why trial geography is not a shortlist
Where studies happen reflects who funds and who authorises them. Treating that as a ranking of care quality confuses the research system with the treatment market, two things that overlap far less than medical-tourism marketing implies.
Before treating geography as a shortlist, read the legality overview by country and what "best country" actually means here.
When these studies started
Registrations by start year since 2020: 2020 (1), 2021 (6), 2022 (2), 2023 (4), 2024 (5), 2025 (4), 2026 (1). Activity for this condition spans 2005 to 2026, which shows whether interest is growing, flat or past its peak.
Frequently asked
Which countries run stem-cell trials for Liver Cirrhosis?
Sites are registered in 19 countries; the largest is China (~54% of country mentions, 2026-08-29).
Does a country with many trials mean better treatment there?
It does not follow. A country can host many trials and still have an unregulated commercial sector selling something quite different to visitors.
Are trial sites and commercial clinics the same thing?
Mostly no. Some clinics imply an association with local research institutions; the registry record names the actual sponsor and site, which settles it.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.
More on this condition
- Liver Cirrhosis: cell-therapy evidence and registered trials
- How much does stem cell therapy for Liver Cirrhosis cost? (2026)
- Liver Cirrhosis stem cell therapy — your questions answered (2026)
- Liver Cirrhosis: cell-therapy evidence by therapy class
- MSC vs HSCT for Liver Cirrhosis: what the registries show